Follow-The-Filings

Security · featured owners

AVTX Avalo Therapeutics Inc.

Health Care COM NEW Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.2%
  • $46M
  • 1 add

AVTX (Avalo Therapeutics Inc.) is held in 1 featured 13F book as of 2026 Q2. Farallon Capital Management is the largest tracked holder by portfolio weight (0.21%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.2% (Farallon Capital Management) · not free-float ownership

  1. Farallon Capital Management Add 0.21%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Farallon Capital Management 2026 Q2 0.21% Add +172.7% 2,498,000 $46M History

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 9 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B3 Filing Doc
8-K 5.02 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 3.02,3.03,5.02,5.03,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 12 rows shown

Filed Form Detail Links
4 Period Sep 16, 2026 Filing Doc
4 Period Sep 10, 2026 Filing Doc
4 Period Aug 28, 2026 Filing Doc
4 Period Aug 17, 2026 · 2 forms Filing Doc
4 Period Aug 10, 2026 Filing Doc
4 Period Aug 11, 2026 Filing Doc
4 Period Jul 27, 2026 Filing Doc
4 Period Jun 30, 2026 · 4 forms Filing Doc
4 Period Jun 23, 2026 · 2 forms Filing Doc
4 Period Jun 10, 2026 · 4 forms Filing Doc
4 Period Jun 2, 2026 · 6 forms Filing Doc
4 Period May 28, 2026 Filing Doc

Updated 11 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.92M $0.441M $0.059M
Gross profit * $640,000 — —
Gross margin * 33.3% — —
Net income -$31.54M -$35.13M -$78.26M
Net margin * -1639.5% -7965.8% -132642.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $8.4M $138.89M $105.29M
Total non-current assets * $12.6M $11.84M $11.17M
Total assets $20.99M $150.73M $116.46M
Total current liabilities $4.62M $6.96M $12.94M
Total non-current liabilities * $9.07M $10.74M $20.47M
Total equity $7.3M $133.03M $83.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$30.68M -$49.06M -$51.46M
Cash from investing -$0.133M $0.356M -$81.72M
Cash from financing $25.04M $175.85M $14.59M
Net change in cash -$5.77M $127.15M -$118.59M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders